Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STRO 5.01 +0.46(10.11%)
Will STRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Other News for STRO
Sutro Biopharma announces initiation of REFRalphaME-L1 Phase 2 trial
Sutro Biopharma Announces Initiation of REFR?ME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma price target lowered by $3 at Truist, here's why
Truist Financial Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Sutro Biopharma GAAP EPS of -$0.59, revenue of $25.7M